Main Findings at the End of Follow-up in the Four Serologic Groups
| . | Group . | |||
|---|---|---|---|---|
| . | A . | B . | C . | D . |
| Anti-HCV | − | − | + | + |
| HCV-RNA | − | + | + | − |
| Male/female | 22/25 | 9/11 | 17/11 | 9/9 |
| Mean age (mo ± SD) | 266 ± 50 | 253 ± 34 | 300 ± 54 | 297 ± 40 |
| Mean follow-up (mo ± SD) | 166 ± 35 | 168 ± 23 | 187 ± 32 | 197 ± 37 |
| Mean ALT ± SD (IU/L) | 17 ± 7 | 18 ± 9 | 68 ± 94 | 21 ± 14 |
| Mean albumin ± SD (g/L) | 4.9 ± 0.31 | 5.1 ± 0.4 | 5.06 ± 0.3 | 5.0 ± 0.4 |
| Mean γ globulin ± SD (g/L) | 1.03 ± 0.19 | 1.02 ± 0.19 | 1.15 ± 0.22 | 0.9 ± 0.29 |
| Mean bilirubin ± SD (mg/dL) | 0.17 ± 0.10 | 0.26 ± 0.17 | 0.20 ± 0.09 | 0.17 ± 0.08 |
| Mean platelets ± SD (× 1,000/μL) | 231 ± 57 | 222 ± 53 | 225 ± 43 | 237 ± 49 |
| . | Group . | |||
|---|---|---|---|---|
| . | A . | B . | C . | D . |
| Anti-HCV | − | − | + | + |
| HCV-RNA | − | + | + | − |
| Male/female | 22/25 | 9/11 | 17/11 | 9/9 |
| Mean age (mo ± SD) | 266 ± 50 | 253 ± 34 | 300 ± 54 | 297 ± 40 |
| Mean follow-up (mo ± SD) | 166 ± 35 | 168 ± 23 | 187 ± 32 | 197 ± 37 |
| Mean ALT ± SD (IU/L) | 17 ± 7 | 18 ± 9 | 68 ± 94 | 21 ± 14 |
| Mean albumin ± SD (g/L) | 4.9 ± 0.31 | 5.1 ± 0.4 | 5.06 ± 0.3 | 5.0 ± 0.4 |
| Mean γ globulin ± SD (g/L) | 1.03 ± 0.19 | 1.02 ± 0.19 | 1.15 ± 0.22 | 0.9 ± 0.29 |
| Mean bilirubin ± SD (mg/dL) | 0.17 ± 0.10 | 0.26 ± 0.17 | 0.20 ± 0.09 | 0.17 ± 0.08 |
| Mean platelets ± SD (× 1,000/μL) | 231 ± 57 | 222 ± 53 | 225 ± 43 | 237 ± 49 |